Risultati per: BRCA e Adenoma del pancreas metastatico
Questo è quello che abbiamo trovato per te
Tu1446 CYSTIC PANCREAS NEUROENDOCRINE TUMORS: A NATURAL HISTORY NOT TO BE UNDERESTIMATED
Tu1431 IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), GALLBLADDER DISEASE PREDICTS TUMOR IN HEAD AND NECK OF THE PANCREAS
Mo1926 A NOVEL STUDY OF THE MICROBIOME IN CHRONIC PANCREATITIS USING MOLECULAR FINGERPRINTING OF PANCREAS FLUID
Tu2021 IMPACT OF ARTIFICIAL INTELLIGENCE ON ADENOMA DETECTION RATE OF GASTROENTEROLOGISTS AT A TERTIARY CARE ENDOSCOPY SUITE: A QUALITY IMPROVEMENT STUDY AND STATISTICAL ANALYSIS
EP122 OMEGA-3 INTAKE LINKED TO COLORECTAL ADENOMA INCIDENCE: A PROSPECTIVE, MULTI-CENTER KOREAN STUDY
Mo1416 PANCREAS-SPECIFIC TRPV6 DELETION DETERIORATES SPINK1 LOSSINDUCED PANCREATIC ATROPHY
945 SHOULD THE ADENOMA DETECTION RATE QUALITY METRIC VARY BY AGE: AN EXPLORATORY ANALYSIS
Assistenza di sopravvivenza per persone affette da cancro avanzato o metastatico: linea guida
Breast Cancer and Pregnancy in Young BRCA Carriers
To the Editor In the article by Dr Lambertini and colleagues on pregnancy after breast cancer in young BRCA carriers, the authors compared the outcomes of patients with breast cancer and BRCA1 or BRCA2 variants according to whether or not they had a pregnancy after having breast cancer. They found no effect of pregnancy on the outcome of disease-free survival (local recurrence, contralateral breast cancer, distant recurrence) (hazard ratio, 0.99; 95% CI, 0.81-1.20) but found a significant improvement in breast cancer–specific survival (death due to breast cancer) with pregnancy (hazard ratio, 0.53; 95% CI, 0.37-0.74; P
Breast Cancer and Pregnancy in Young BRCA Carriers—Reply
In Reply We thank Dr Narod for his comment on our recent research article evaluating the safety of pregnancy following breast cancer in young women with germline BRCA pathogenic or likely pathogenic variants. In his Letter, Narod noted that our primary analysis did not control for the potentially protective effect of risk-reducing bilateral salpingo-oophorectomy in this patient cohort.
Test promettenti su vaccino anti-recidive del tumore al pancreas
Sperimentale e terapeutico, è basato su Rna
Predictive value of anthropometric and biochemical indices in non-alcoholic fatty pancreas disease: a cross-sectional study
Objectives
Triglyceride (TG), triglyceride-glucose index (TyG), body mass index (BMI), TyG-BMI and triglyceride to high-density lipoprotein ratio (TG/HDL) have been reported to be reliable predictors of non-alcoholic fatty liver disease. However, there are few studies on potential predictors of non-alcoholic fatty pancreas disease (NAFPD). Our aim was to evaluate these and other parameters for predicting NAFPD.
Design
Cross-sectional study design.
Setting
Physical examination centre of a tertiary hospital in China.
Participants
This study involved 1774 subjects who underwent physical examinations from January 2016 to September 2016.
Primary and secondary outcome measures
From each subject, data were collected for 13 basic physical examination and blood biochemical parameters: age, weight, height, BMI, TyG, TyG-BMI, high-density lipoprotein (HDL), low-density lipoprotein, total cholesterol, TG, fasting plasma glucose, TG/HDL and uric acid. NAFPD was diagnosed by abdominal ultrasonography. A logistic regression model with a restricted cubic spline was used to evaluate the relationship between each parameter and NAFPD. The receiver operating characteristic (ROC) curve was used to calculate the area under the curve for each parameter.
Results
HDL was negatively correlated with NAFPD, height was almost uncorrelated with NAFPD and the remaining 11 parameters were positively correlated with NAFPD. ROC curve showed that weight-related parameters (weight, BMI and TyG-BMI) and TG-related parameters (TyG, TG and TG/HDL) had high predictive values for the identification of NAFPD. The combinations of multiple parameters had a better prediction effect than a single parameter. All the predictive effects did not differ by sex.
Conclusions
Weight-related and TG-related parameters are good predictors of NAFPD in all populations. BMI showed the greatest predictive potential. Multiparameter combinations appear to be a good way to predict NAFPD.
Preoperative pancreatic stent placement before the enucleation of insulinoma located in the head and neck of the pancreas in proximity to the main pancreatic duct: study protocol for a multicentre randomised clinical trial in Chinese tertiary medical centres
Introduction
The surgical intervention approach to insulinomas in proximity to the main pancreatic duct remains controversial. Standard pancreatic resection is recommended by several guidelines; however, enucleation (EN) still attracts surgeons with less risk of late exocrine/endocrine insufficiency, despite a higher postoperative pancreatic fistula (POPF) rate. Recently, the efficacy and safety of preoperative pancreatic stent placement before the EN have been demonstrated. Thus, a multicentre open-label study is being conducted to evaluate the efficacy and safety of stent placement in improving the outcome of EN of insulinomas in proximity to the main pancreatic duct.
Methods and analysis
This is a prospective, randomised, open-label, superiority clinical trial conducted at multiple tertiary centres in China. The major eligibility criterion is the presence of insulinoma located in the head and neck of the pancreas in proximity (≤2 mm) to the main pancreatic duct. Blocked randomisation will be performed to allocate patients into the stent EN group and the direct EN group. Patients in the stent EN group will go through stent placement by the endoscopist within 24 hours before the EN surgery, whereas other patients will receive EN surgery directly. The primary outcome is the assessment of the superiority of stent placement in reducing POPF rate measured by the International Study Group of Pancreatic Surgery standard. Both interventions will be performed in an inpatient setting and regular follow-up will be performed. The primary outcome (POPF rate) will be tested for superiority with the X2 test. The difference in secondary outcomes between the two groups will be analysed using appropriate tests.
Ethics and dissemination
The study has been approved by the Peking Union Medical College Hospital Institutional Review Board (K23C0195), Ruijin Hospital Ethics Committee (2023-314), Peking University First Hospital Ethics Committee (2024033-001), Institutional Review Board of Xuanwu Hospital of Capital Medical University (2023223-002), Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (XJTU1AF2023LSK-473), Institutional Review Board of Tongji Medical College Tongji Hospital (TJ-IRB202402059), Ethics Committee of Tongji Medical College Union Hospital (2023-0929) and Shanghai Cancer Center Institutional Review Board (2309282-16). The results of the study will be published in an international peer-reviewed journal.
Trial registration number
NCT05523778.
Istituita la cabina di regia per la Rete Centri Pancreas Unit
Al ministero della Salute, coordinata da Sergio Alfieri
Salute, istituita cabina di regia per la Rete Centri Pancreas Unit
Comunicato del 20/03/2024 n°16